Characteristics of patients with proven, probable, and possible IA

Patient no.Gender/age (yr)aUnderlying diseasebType of IASteroidscDuration of neutropenia (days)No. of positive samples/total no. of samplesHighest level of glucan (pg/ml)Organ involvement of IASite(s) of isolation/Aspergillus speciesbHRCT scanDeath in relation to IA
1M/70MDSProven269/13>523LungsTBB/A. fumigatusNodules in lungsNo
2F/65NHLProven+103/6>523LungsTBB/A. fumigatusNodules in lungsYes
3F/29AMLProven+349/6>523Lungs, brainSputum/A. fumigatusNodules in lungNo
Abcess/A. fumigatusPleural effusion
4F/30AMLProven6610/24>523Lungs, subcutaneous tissueSubcutaneous nodule/A. flavusNodules in lungsNo
5F/44CLLProven+324/12>523LungsTBB/A. fumigatusBilateral infiltrate in lungsNo
6M/45AMLProbable+300/9LungsBAL/A. fumigatusNodules in lungsNo
7M/70MDSProbable+238/18>523LungsSputum/A. fumigatusNodules in lungsNo
8F/32AMLProbable+269/9>523LungsSputum/A. fumigatusNodules in lungsYes
Pleural effusion
9M/20ALLPossible280/8LungsNodule in lungsNo
10M/25ALLPossible+310/14LungsNodules in lungsNo
11F/54AMLPossible6012/16>523LungsPleural effusionYes
  • a M, male; F, female.

  • b MDS, myelodysplastic syndrome; NHL, non-Hodgkin's lymphoma; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; ALL, acute lymphocytic leukemia; TBB, transbronchial biopsy.

  • c +, administered; −, not administered.